| TrivarX Appoints Emeritus Research for Phase 1 Study | Nov 10, 2026 | Operations update | ASX |
|---|
| September 2026 Quarterly Activities Report and Appendix 4C | Oct 29, 2026 | Quarterly report | ASX |
|---|
| September 2026 Quarterly Activities Report and Appendix 4C | Oct 29, 2026 | Quarterly report | ASX |
|---|
| Letter to Shareholders & Notice of AGM & Proxy Form | Oct 26, 2026 | Meeting notice | ASX |
|---|
| Syntro Health Appointed to Support Stabl-Im Clinical Program | Oct 21, 2026 | Operations update | ASX |
|---|
| Syntro Health Appointed to Support Stabl-Im Clinical Program | Oct 21, 2026 | Operations update | ASX |
|---|
| Change of Director's Interest Notice - David Trimboli | Oct 14, 2026 | Ownership change notice | ASX |
|---|
| Change of Director's Interest Notice - Chris Ntoumenopoulos | Oct 14, 2026 | Ownership change notice | ASX |
|---|
| Notification of cessation of securities - TRI | Oct 14, 2026 | Financing | ASX |
|---|
| Appendix 4G | Sep 29, 2026 | Other filings | ASX |
|---|
| Corporate Governance Statement | Sep 29, 2026 | Other filings | ASX |
|---|
| 2026 Annual Report | Sep 29, 2026 | Annual report | ASX |
|---|
| Stabl-Im Clinical Development Update | Sep 22, 2026 | Operations update | ASX |
|---|
| Notice of AGM and Closing Date for Director Nominations | Sep 21, 2026 | Meeting notice | ASX |
|---|
| Appendix 4E - Preliminary Final Report | Aug 26, 2026 | Results | ASX |
|---|
| June 2026 Quarterly Activities Report and Appendix 4C | Jul 28, 2026 | Quarterly report | ASX |
|---|
| Stabl-Im clinical trial supply milestone achieved | Jul 15, 2026 | Operations update | ASX |
|---|
| CRO Engaged to Advance Stabl-Im Phase 1 Trial | May 21, 2026 | Operations update | ASX |
|---|
| March 2026 Quarterly Activities Report and Appendix 4C | Apr 29, 2026 | Quarterly report | ASX |
|---|
| Dr Danielle Meyrick appointed as CEO | Apr 28, 2026 | Management or board change | ASX |
|---|
| Appendix 4D & Half-Year Financial Report to 31 December 2025 | Feb 24, 2026 | Interim report | ASX |
|---|
| December 2025 Quarterly Activities Report and Appendix 4C | Jan 29, 2026 | Quarterly report | ASX |
|---|
| Positive results from US-veteran mental health trial | Dec 17, 2025 | Results | ASX |
|---|
| TRI Exercises Option to Advance Acquisition of Stabl-Im | Nov 4, 2025 | Acquisition or disposal | ASX |
|---|
| September 2025 Quarterly Activities Report and Appendix 4C | Oct 30, 2025 | Quarterly report | ASX |
|---|
| US-veteran mental health trial patient recruitment complete | Oct 21, 2025 | Operations update | ASX |
|---|
| Acquisition of Stabl-Im technology and Private Placement | Oct 15, 2025 | Financing | ASX |
|---|
| Reinstatement to Official Quotation | Oct 15, 2025 | Trading halt or suspension | ASX |
|---|
| Extension of Trading Suspension | Oct 12, 2025 | Trading halt or suspension | ASX |
|---|
| Suspension from Quotation | Oct 8, 2025 | Trading halt or suspension | ASX |
|---|
| Inadvertent Lift of Trading Halt | Oct 8, 2025 | Trading halt or suspension | ASX |
|---|
| Pause in trade | Oct 7, 2025 | Trading halt or suspension | ASX |
|---|
| Positive interim results from US-veteran focused trial | Oct 7, 2025 | Results | ASX |
|---|
| Trading Halt | Oct 6, 2025 | Trading halt or suspension | ASX |
|---|
| Appendix 4E - Preliminary Final Report | Aug 28, 2025 | Results | ASX |
|---|
| June 2025 Quarterly Activities Report and Appendix 4C | Jul 30, 2025 | Quarterly report | ASX |
|---|
| First patient recruited in innovative mental health trial | Jun 18, 2025 | Operations update | ASX |
|---|
| March 2025 Quarterly Activities Report and Appendix 4C | Apr 30, 2025 | Quarterly report | ASX |
|---|
| IRB approval for trial with US Dept of Veterans Affairs | Apr 27, 2025 | Operations update | ASX |
|---|
| TrivarX Receives Firm Commitments to Raise $2.25 million | Mar 16, 2025 | Financing | ASX |
|---|
| Trial with US Department of Veterans Affairs | Mar 12, 2025 | Operations update | ASX |
|---|
| Appendix 4D & Half-Year Financial Report to 31 December 2024 | Feb 28, 2025 | Interim report | ASX |
|---|
| December 2024 Quarterly Activities Report and Appendix 4C | Jan 30, 2025 | Quarterly report | ASX |
|---|
| TrivarX Receives $1.03m R&D Tax Incentive | Dec 5, 2024 | Other filings | ASX |
|---|
| New AI Tool Expands Patient Reach and Market Opportunities | Nov 6, 2024 | Operations update | ASX |
|---|
| September 2024 Quarterly Activities Report and Appendix 4C | Oct 30, 2024 | Quarterly report | ASX |
|---|
| June 2024 Quarterly Activities Report and Appendix 4C | Jul 31, 2024 | Quarterly report | ASX |
|---|
| Positive Results from Phase 2 SAMDE Study | Jul 29, 2024 | Other filings | ASX |
|---|
| TrivarX Receives Firm Commitments to Raise $2.5 million | May 1, 2024 | Other filings | ASX |
|---|
| March 2024 Quarterly Activities Report and Appendix 4C | Apr 29, 2024 | Quarterly report | ASX |
|---|
| Appendix 4D & Half-Year Financial Report to 31 December 2023 | Feb 28, 2024 | Interim report | ASX |
|---|
| Response to ASX Price Query | Feb 22, 2024 | Explanation request | ASX |
|---|
| TrivarX Receives $888k R&D Tax Incentive | Feb 7, 2024 | Other filings | ASX |
|---|
| TRI-001 Algorithm and Phase 2 Trial Update | Feb 4, 2024 | Other filings | ASX |
|---|
| December 2023 Quarterly Activities Report and Appendix 4C | Jan 31, 2024 | Quarterly report | ASX |
|---|
| Phase 2 SAMDE Study Update | Nov 19, 2023 | Other filings | ASX |
|---|
| Board and Management Transition | Oct 5, 2023 | Other filings | ASX |
|---|
| Letter to Shareholders & Notice of GM & Proxy Form | Sep 6, 2023 | Other filings | ASX |
|---|
| Phase 2 Trial Commences for SAMDE Study | Sep 3, 2023 | Other filings | ASX |
|---|
| Proposed issue of securities - MEB | Aug 7, 2023 | Financing | ASX |
|---|
| Medibio Receives Firm Commitments to Raise $2.25m | Aug 7, 2023 | Other filings | ASX |
|---|
| June 2023 Quarterly Activities Report and Appendix 4C | Jul 30, 2023 | Quarterly report | ASX |
|---|
| Phase 1 Trial Completed for SAMDE Study | Jul 23, 2023 | Other filings | ASX |
|---|
| Medibio Completes Share Purchase Plan | May 29, 2023 | Financing | ASX |
|---|
| March 2023 Quarterly Activities Report and Appendix 4C | Apr 26, 2023 | Quarterly report | ASX |
|---|
| MEB Executes Bridging Loans with Directors | Apr 21, 2023 | Other filings | ASX |
|---|
| Share Purchase Plan Supplementary Prospectus | Apr 14, 2023 | Financing | ASX |
|---|
| Share Purchase Plan Prospectus | Mar 1, 2023 | Financing | ASX |
|---|
| Half Yearly Report and Accounts | Feb 24, 2023 | Interim report | ASX |
|---|
| MEB to Raise up to $2.75 million By Way of a Placement & SPP | Feb 14, 2023 | Financing | ASX |
|---|
| Medibio Quarterly Update and Cashflow Report | Jan 30, 2023 | Other filings | ASX |
|---|
| Medibio Receives R&D Tax Incentive Refund | Nov 14, 2022 | Other filings | ASX |
|---|
| Medibio Appoints CEO | Sep 19, 2022 | Other filings | ASX |
|---|
| Appendix 4E and Preliminary Final Report | Aug 31, 2022 | Results | ASX |
|---|
| Sleep Analysis Depressive Burden Study Clinical Trial | Jul 20, 2022 | Other filings | ASX |
|---|
| MEB to Raise $1.4m by way of a Placement & MD/CEO Resigns | Jun 22, 2022 | Financing | ASX |
|---|
| Reinstatement to Quotation | Jun 22, 2022 | Trading halt or suspension | ASX |
|---|
| Voluntary Suspension | Jun 16, 2022 | Trading halt or suspension | ASX |
|---|
| FDA Confirm Diagnostic Method on Depression Validation Trial | May 18, 2022 | Other filings | ASX |
|---|
| Medibio Announces Entitlement Offer Result | Mar 10, 2022 | Financing | ASX |
|---|
| Termination of Underwriting Agreement | Mar 1, 2022 | Other filings | ASX |
|---|
| Non-Renounceable Entitlement Offer Underwriting Update | Jan 20, 2022 | Financing | ASX |
|---|
| MEB to Raise up to $5.7 million by way of a Placement & NREO | Dec 14, 2021 | Financing | ASX |
|---|
| FDA Strategy and Regulatory Update | Oct 25, 2021 | Other filings | ASX |
|---|
| Appendix 4E and Annual Report | Aug 31, 2021 | Annual report | ASX |
|---|
| MEB Appoints R&CPMK As Communications Agency in the US | Jun 24, 2021 | Other filings | ASX |
|---|
| Medibio strengthens its IP protection | May 3, 2021 | Other filings | ASX |
|---|
| Re-submission of FDA 510(k) application | Apr 28, 2021 | Other filings | ASX |
|---|
| Consumer Mental Health App Development - Second Test Phase | Apr 21, 2021 | Other filings | ASX |
|---|
| MEB Share Purchase Plan Closes Strongly Oversubscribed | Mar 31, 2021 | Financing | ASX |
|---|
| Supplementary Prospectus | Mar 31, 2021 | Offer document | ASX |
|---|
| MEB Begins Implementation of ilumen In the United Kingdom | Mar 18, 2021 | Other filings | ASX |
|---|
| Underwritten Share Purchase Plan Update | Feb 15, 2021 | Financing | ASX |
|---|
| MEB to Raise up to $3.5m By Way of a Placement and SPP | Feb 10, 2021 | Financing | ASX |
|---|
| Medibio Granted CE Mark Approval for MEBsleep | Jan 18, 2021 | Other filings | ASX |
|---|
| Consumer Mental Health App Initial testing phase commenced | Jan 10, 2021 | Other filings | ASX |
|---|
| US FDA advises further data needed for MEBsleep approval | Dec 28, 2020 | Other filings | ASX |
|---|
| Update on Breakthrough Device Program | Dec 3, 2020 | Other filings | ASX |
|---|
| Global Master License & Services Agreement with Compass | Nov 22, 2020 | Other filings | ASX |
|---|
| AGM Presentation | Nov 12, 2020 | Other filings | ASX |
|---|
| MEB Signs Clinical Trial Agreement with MedBridge Healthcare | Oct 6, 2020 | Other filings | ASX |
|---|
| Request For FDA Breakthrough Device Designation Submitted | Oct 1, 2020 | Other filings | ASX |
|---|
| Patent Granted to Monitor Stress Conditions Using Heartrate | Aug 9, 2020 | Other filings | ASX |
|---|
| Entitlement Issue Results | Jul 9, 2020 | Financing | ASX |
|---|
| Entitlement Offer Booklet | Jun 10, 2020 | Financing | ASX |
|---|
| Placement and Fully Underwritten Entitlement Offer | Jun 9, 2020 | Financing | ASX |
|---|
| Medibio submits FDA 510K Application to FDA | Apr 29, 2020 | Other filings | ASX |
|---|
| Final Compass Pilot Completed Successfully | Apr 8, 2020 | Other filings | ASX |
|---|
| Strategic Plan for FDA and CE Mark Approval | Feb 13, 2020 | Other filings | ASX |
|---|
| Company Update | Dec 8, 2019 | Other filings | ASX |
|---|
| Results of Annual General Meeting | Nov 22, 2019 | Meeting outcome | ASX |
|---|
| Pause in Trading | Nov 21, 2019 | Trading halt or suspension | ASX |
|---|
| Medibio Signs Agreement with PwC Australia for ilumen | Oct 23, 2019 | Other filings | ASX |
|---|
| MEB successfully completes first Ilumen pilot with Compass | Oct 20, 2019 | Other filings | ASX |
|---|
| Medibio Announces Results of Review of Partly Paid Shares | Sep 26, 2019 | Other filings | ASX |
|---|
| Fourth Pilot Agreement Signed with Compass Group for ilumen | Aug 30, 2019 | Other filings | ASX |
|---|
| Board Changes and Establishment of Advisory Board | Aug 29, 2019 | Other filings | ASX |
|---|
| MEB Signs Compass Group Australia to ilumen | Jul 29, 2019 | Other filings | ASX |
|---|
| MEB Partners with Corporate Wellness Solution Leader WellteQ | Jul 28, 2019 | Other filings | ASX |
|---|
| MEB Signs Second Compass Group PLC Pilot for ilumen | Jul 19, 2019 | Other filings | ASX |
|---|
| MEB Raises $4.02m via Placement and Fully Underwritten SPP | Jul 9, 2019 | Financing | ASX |
|---|
| Suspension from Official Quotation | Jul 8, 2019 | Trading halt or suspension | ASX |
|---|
| MEB Signs Compass Group to ilumen | Jun 30, 2019 | Other filings | ASX |
|---|
| Response to Appendix 4C Query | May 20, 2019 | Quarterly report | ASX |
|---|
| Regulatory and Commercialisation Strategy Update | Apr 29, 2019 | Other filings | ASX |
|---|
| Sponsored Research Agreement with Humanitas University | Apr 16, 2019 | Other filings | ASX |
|---|
| MEB Outsources Psychology Services in support of ilumen | Mar 13, 2019 | Other filings | ASX |
|---|
| Entitlement Issue Results and Shortfall Notification | Mar 12, 2019 | Financing | ASX |
|---|
| Ilumen Successfully Completes First Commercial Program | Mar 6, 2019 | Other filings | ASX |
|---|
| Converting Note & Non-Renounceable Entitlement Offer | Dec 9, 2018 | Financing | ASX |
|---|
| Exclusive Agreement Signed for ilumen Pilot Program | Nov 26, 2018 | Other filings | ASX |
|---|
| Response to ASX Appendix 4C Query | Nov 14, 2018 | Explanation request | ASX |
|---|
| Medibio Provides Update on FDA Process | Nov 8, 2018 | Other filings | ASX |
|---|
| Medibio Appoints CEO and Managing Director | Nov 1, 2018 | Other filings | ASX |
|---|
| MEB Signs ilumen Contract with Large Australian Employer | Oct 23, 2018 | Other filings | ASX |
|---|
| Receipt of R&D Tax Incentive Refund | Oct 14, 2018 | Other filings | ASX |
|---|
| Medibio Releases Corporate Health Product, ilumen | Oct 3, 2018 | Other filings | ASX |
|---|
| Notice Received Under Section 249D of the Corporations Act | Oct 1, 2018 | Other filings | ASX |
|---|
| Executive Leadership Changes | Sep 20, 2018 | Other filings | ASX |
|---|
| Clinical Study Shows Improvement to Diagnostic Standard | Sep 5, 2018 | Other filings | ASX |
|---|
| Preliminary Final Report | Aug 29, 2018 | Results | ASX |
|---|
| Departure of Managing Director & Chief Executive Officer | Aug 28, 2018 | Other filings | ASX |
|---|
| Medibio Submits FDA De Novo Application | Jul 15, 2018 | Other filings | ASX |
|---|
| Medibio Receives TGA Approval | Jun 19, 2018 | Other filings | ASX |
|---|
| MEB Signs Global Contract with Jacobs Engineering | May 25, 2018 | Other filings | ASX |
|---|
| Medibio Announces Next Tranche of Corporate Health Contracts | May 9, 2018 | Other filings | ASX |
|---|
| Medibio Signs First Corporate Health Contract | May 8, 2018 | Other filings | ASX |
|---|
| Medibio Receives CE Certification | May 2, 2018 | Other filings | ASX |
|---|
| MEB signs binding term sheet to acquire Vital Conversations | Mar 4, 2018 | Acquisition or disposal | ASX |
|---|
| Medibio Quarterly Update and Cash Flow Report | Jan 30, 2018 | Other filings | ASX |
|---|
| Agreement with Striiv to Accelerate Commercialisation | Jan 21, 2018 | Other filings | ASX |
|---|
| Medibio Announces ISO 13485 Certification | Jan 10, 2018 | Other filings | ASX |
|---|
| Medibio & Mayo Clinic collaborate on depression technology | Dec 13, 2017 | Other filings | ASX |
|---|
| Appendix 4C - quarterly | Oct 30, 2017 | Quarterly report | ASX |
|---|
| MEB completes heavily oversubscribed institutional placement | Oct 12, 2017 | Financing | ASX |
|---|
| Response to ASX Query | Oct 10, 2017 | Explanation request | ASX |
|---|
| Medibio enters into an Agreement with Otsuka Pharmaceutical | Oct 8, 2017 | Other filings | ASX |
|---|
| Medibio enters agreement with Mayo Clinc | Oct 3, 2017 | Other filings | ASX |
|---|
| Medibio initiates confirmatory study | Aug 21, 2017 | Other filings | ASX |
|---|
| Medibio announces positive clinical study results | Aug 2, 2017 | Other filings | ASX |
|---|
| Quarterly ASX Update and Cashflows | Jul 27, 2017 | Other filings | ASX |
|---|
| Scientific breakthrough on objective diagnosis of PTSD | Jun 26, 2017 | Other filings | ASX |
|---|
| Independent researchers present first data validating MEB | Jun 8, 2017 | Other filings | ASX |
|---|
| Signed second agreement for Wellness | May 17, 2017 | Other filings | ASX |
|---|
| MEB Signs Strategic Joint Development Agreement with Mayo Cl | May 10, 2017 | Other filings | ASX |
|---|
| Quarterly ASX Update and Cashflow | Apr 27, 2017 | Other filings | ASX |
|---|
| MEB enters fully funded Paediatric mental illness diagnostic | Apr 10, 2017 | Other filings | ASX |
|---|
| Conversion of Options to Partly Paid shares | Apr 5, 2017 | Other filings | ASX |
|---|
| MEB appoints US med-tech veteran as CEO & Managing Director | Feb 16, 2017 | Other filings | ASX |
|---|
| Early Redemption of Convertible Note | Jan 30, 2017 | Financing | ASX |
|---|
| Partnership with leading US University on PTSD | Jan 24, 2017 | Other filings | ASX |
|---|
| Excellent performance in the pilot phase of US Validation | Dec 20, 2016 | Other filings | ASX |
|---|
| Medibio enters into binding agreement with Medtronic | Nov 24, 2016 | Other filings | ASX |
|---|
| Capital raising of $13.5million to accelerate growth | Nov 17, 2016 | Financing | ASX |
|---|
| Outstanding 86% accuracy in 889 person Ottawa Uni study | Nov 1, 2016 | Other filings | ASX |
|---|
| Quarterly Activities Report | Oct 31, 2016 | Quarterly report | ASX |
|---|
| Receipt of $3,074,224 R & D Tax Incentive Refund | Oct 14, 2016 | Other filings | ASX |
|---|
| Partners with HBF and Vital Conversations on mental health | Oct 10, 2016 | Other filings | ASX |
|---|
| Funding Update | Oct 9, 2016 | Other filings | ASX |
|---|
| Medibio and Monash Groundbreaking partnership on innovation | Sep 14, 2016 | Other filings | ASX |
|---|
| Commercial Trial and Validation Update | Aug 17, 2016 | Other filings | ASX |
|---|
| Breakthrough validation of depression test with Ottawa Univ | Aug 8, 2016 | Other filings | ASX |
|---|
| MEB Advanced Analytics Cloud Solution breaks new ground in S | Jun 24, 2016 | Other filings | ASX |
|---|
| Medibios first commercial pilot study a success | May 30, 2016 | Other filings | ASX |
|---|
| Appendix 4C - quarterly & activities report | May 1, 2016 | Quarterly report | ASX |
|---|
| Medibio Acquires Key IP | Apr 19, 2016 | Acquisition or disposal | ASX |
|---|
| Successful Pre-Submission Meeting with the US FDA | Mar 31, 2016 | Other filings | ASX |
|---|
| Medibio appoints US based CRO for its validation trials | Mar 30, 2016 | Other filings | ASX |
|---|
| 4 leading US Institutions provide Medibio 10,000 data sets | Mar 11, 2016 | Other filings | ASX |
|---|
| Swinburne Software Labs trial success with Apple Watch & FIT | Mar 8, 2016 | Other filings | ASX |
|---|
| Partnership to evaluate wearable applications for Mental Hea | Feb 11, 2016 | Other filings | ASX |
|---|
| MEB signs MOU with $100 billion NYSE listed medical company | Feb 10, 2016 | Other filings | ASX |
|---|
| BPO: BioProspect and Solagran agreement to commercialise | Feb 25, 2010 | Other filings | ASX |
|---|